Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosing Interruption of Natalizumab in MS
NCT04048577Phase 4Unknown
- Sponsor
- TrueMed Therapeutics
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in multiple sclerosis (MS), sponsored by TrueMed Therapeutics. Status: unknown.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04048577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048577.